{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05444894",
      "title": "EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia",
      "start_date": "2022-04-29",
      "completion_date": "2025-12",
      "enrollment": 0,
      "sponsor": "Editas Medicine, Inc."
    },
    {
      "nct_id": "NCT03396042",
      "title": "Natural History Study of CEP290-Related Retinal Degeneration",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Blindness, Leber Congenital Amaurosis 10, Vision Disorders, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease, Retinal Degeneration",
      "start_date": "2017-12-17",
      "completion_date": "2022-05-06",
      "enrollment": 0,
      "sponsor": "Editas Medicine, Inc."
    },
    {
      "nct_id": "NCT04853576",
      "title": "A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Sickle Cell Disease, Hemoglobinopathies",
      "start_date": "2021-05-04",
      "completion_date": "2025-08",
      "enrollment": 0,
      "sponsor": "Editas Medicine, Inc."
    },
    {
      "nct_id": "NCT06363760",
      "title": "A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent \u03b2-Thalassemia Who Received EDIT-301",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "",
      "condition": "Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies",
      "start_date": "2024-06-17",
      "completion_date": "2040-08",
      "enrollment": 0,
      "sponsor": "Editas Medicine, Inc."
    },
    {
      "nct_id": "NCT03872479",
      "title": "Single Ascending Dose Study in Participants With LCA10",
      "status": "UNKNOWN",
      "phase": "PHASE1, PHASE2",
      "condition": "Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital",
      "start_date": "2019-09-26",
      "completion_date": "2025-05-23",
      "enrollment": 0,
      "sponsor": "Editas Medicine, Inc."
    }
  ],
  "summary": {
    "total_trials": 5,
    "by_phase": {
      "PHASE1, PHASE2": 3,
      "": 2
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 2,
      "COMPLETED": 1,
      "ENROLLING_BY_INVITATION": 1,
      "UNKNOWN": 1
    },
    "active_trials": 3,
    "completed_trials": 1,
    "conditions": [
      "Blindness, Leber Congenital Amaurosis 10, Vision Disorders, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease, Retinal Degeneration",
      "Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital",
      "Sickle Cell Disease, Hemoglobinopathies",
      "Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies",
      "Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia"
    ],
    "lead_stage": "unknown"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:06.900712",
    "search_query": "Editas Medicine, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Editas+Medicine,+Inc."
  }
}